Unknown

Dataset Information

0

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma.


ABSTRACT: The expression levels of CTLA-4 and CD28 were analyzed in 191 nasopharyngeal carcinoma (NPC) patients diagnosed and treated at our hospital between January 2010 and November 2011. The 3-year overall survival (OS) rate (91.4% vs. 81.2%,p = 0.043), failure-free survival (FFS) rate (82.8% vs. 68.0%, p = 0.009) and distant failure-free survival (D-FFS) rate (85.8% vs. 72.3%, p = 0.006) in the low tumor CTLA-4 expression group was higher than in the high tumor CTLA-4 group. There were no differences between the locoregional failure-free survival (LR-FFS) rates in the high and low tumor CTLA-4 expression groups. Moreover, no differences in the OS, FFS, D-FFS, or LR-FFS were observed between the groups with high and low lymphocyte CTLA-4 levels, high and low tumor CD28 levels, or high and low lymphocyte CD28 levels. Cox regression analysis confirmed the prognostic value of tumor CTLA-4 expression, particularly for D-FFS, in NPC patients (p = 0.044). NPC patients with high tumor CTLA-4 expression had a poorer prognosis than those with low expression.

SUBMITTER: Huang PY 

PROVIDER: S-EPMC4914341 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma.

Huang Pei-Yu PY   Guo Shan-Shan SS   Zhang Yu Y   Lu Jia-Bin JB   Chen Qiu-Yan QY   Tang Lin-Quan LQ   Zhang Lu L   Liu Li-Ting LT   Zhang Li L   Mai Hai-Qiang HQ  

Oncotarget 20160301 11


The expression levels of CTLA-4 and CD28 were analyzed in 191 nasopharyngeal carcinoma (NPC) patients diagnosed and treated at our hospital between January 2010 and November 2011. The 3-year overall survival (OS) rate (91.4% vs. 81.2%,p = 0.043), failure-free survival (FFS) rate (82.8% vs. 68.0%, p = 0.009) and distant failure-free survival (D-FFS) rate (85.8% vs. 72.3%, p = 0.006) in the low tumor CTLA-4 expression group was higher than in the high tumor CTLA-4 group. There were no differences  ...[more]

Similar Datasets

| S-EPMC2394459 | biostudies-other
| S-EPMC8427601 | biostudies-literature
| S-EPMC6492676 | biostudies-literature
| S-EPMC3726622 | biostudies-literature
| S-EPMC7327006 | biostudies-literature
| S-EPMC5039393 | biostudies-literature
| S-EPMC4558138 | biostudies-literature
| S-EPMC8027117 | biostudies-literature
| S-EPMC4015363 | biostudies-literature